Gan to kagaku ryoho. Cancer & chemotherapy 2013-11-01

[Recurrent gastric cancer treated with fourth-line chemotherapy consisting of capecitabine and cisplatin leading to partial response].

Yoichi Makari, Shohei Iijima, Takashi Doi, Minako Hoshi, Satoshi Oshima, Kimimasa Ikeda, Eiji Kurokawa, Nobuteru Kikkawa

Index: Gan To Kagaku Ryoho. 40(12) , 2265-7, (2013)

Full Text: HTML

Abstract

A 70-year-old man with advanced gastric cancer was treated with neoadjuvant chemotherapy consisting of S-1 plus cisplatin( CDDP). He exhibited symptoms of cerebral infarction during the second course of chemotherapy. Distal gastrectomy was performed and the histological diagnosis was pT3N3aM0, pStage IIIB. Adjuvant chemotherapy was administered; however, after the second course, gastric cancer recurred in the lymph nodes. Second-line chemotherapy with irinotecan (CPT-11) and CDDP was initiated. Thereafter, third-line chemotherapy with docetaxel was performed. However, the response to treatment was progressive disease (PD). Subsequently, fourth-line chemotherapy was performed with capecitabine and CDDP (XP chemotherapy). After the fourth course of XP chemotherapy, the response was partial response (PR). Moreover, PR was maintained after 20 courses of chemotherapy.


Related Compounds

Related Articles:

TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.

2014-09-30

[Oncotarget 5(18) , 8107-22, (2014)]

cIEF for rapid pKa determination of small molecules: a proof of concept.

2014-10-15

[Eur. J. Pharm. Sci. 63 , 14-21, (2014)]

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

2015-01-07

[World J. Gastroenterol. 21(1) , 164-76, (2015)]

Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles.

[Iran. J. Pharm. Res. 14(2) , 395-405, (2015)]

Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line.

2015-08-01

[Cancer Sci. 106 , 1000-7, (2015)]

More Articles...